Novartis AG
CorpDigest
Novartis AG
Company History
Founded 1996 in Basel, Switzerland
Last reviewed: 2026-06-08 · By Swet Parvadiya
Basel, 1996: two of Switzerland's oldest chemical companies — Ciba-Geigy, founded from an 1859 dye manufacturer, and Sandoz, founded in 1886 — completed a merger that created Novartis at the time of announcement the largest corporate merger in history. The combined entity had $36 billion in annual revenue and operations across pharmaceuticals, agriculture, and nutrition. CEO Daniel Vasella, who would run the company until 2010, spent the next decade deciding which of those businesses Novartis actually wanted to be in.
The Alcon ophthalmology business was acquired in 2010 and eventually spun off in 2019. The agricultural chemicals business became Syngenta, spun off in 2000. Each divestiture reflected the same logic: Novartis's competitive advantage was in developing and manufacturing patented medicines, and capital deployed in agriculture or ophthalmology equipment generated lower returns than capital deployed in pharmaceutical R&D. The Chiron Corporation acquisition in 2006 for $5.1 billion brought vaccine technology and oncology assets that aligned with the focused pharmaceutical strategy.
Vas Narasimhan, who became CEO in 2018, inherited a company that had already been significantly narrowed from its 1996 scope but still carried the $10 billion Sandoz generics business as a hedge against patent cliff risk. His decision to exit generics entirely was made with the data that the Sandoz business, despite its scale, was generating returns on invested capital below what the branded pharmaceutical business offered. The spin-off in October 2023 was the structural conclusion of a 25-year simplification process that began when Ciba-Geigy and Sandoz realized they were better as a focused pharmaceutical company than as a diversified chemical conglomerate.
Daniel Vasella is an Italian-Swiss physician and business executive who served as the first CEO of Novartis from 1996 to 2002 and later as Chairman from 2002 to 2012. He played a pivotal role in the 1996 merger of Ciba-Geigy and Sandoz, navigating the cultural clashes and operational redundancies of the two百年old Swiss companies. Vasella's background as a medical doctor gave him a unique perspective on the pharmaceutical industry, driving his focus on innovative drug development and patient-centric research. During his tenure, he oversaw the acquisition of several major biotechnology companies, including the $5.1 billion purchase of Chiron Corporation in 2006, which significantly expanded Novartis's vaccine and oncology capabilities. Vasella was also known for his controversial decision to accept a $78 million severance package in 2013, which sparked public outrage and led to the Swiss 'Minder Initiative' against excessive executive compensation. Despite the controversy, Vasella is widely credited with transforming Novartis from a diversified chemical company into a focused, research-driven pharmaceutical powerhouse.
Markus U. Diethelm is a Swiss business executive who served as the CEO of Sandoz from 1991 to 1996 and as the first Chairman of the Board of Novartis from 1996 to 1999. He was the primary architect of the 1996 merger between Sandoz and Ciba-Geigy, a transaction that created Novartis and reshaped the global pharmaceutical industry. Diethelm's career at Sandoz spanned over three decades, during which he held various leadership positions in finance and operations. His leadership style was characterized by a focus on financial discipline and strategic long-term planning, qualities that were essential in navigating the complex integration of the two companies. After stepping down as Chairman of Novartis in 1999, Diethelm remained active in the business community, serving on the boards of several major Swiss corporations. He is widely respected in Switzerland for his role in creating a global pharmaceutical leader and for his commitment to maintaining the company's headquarters in Basel.
Alexander Clavel and Alfred Kern founded a chemical dye works in Basel, Switzerland, to produce fuchsine, marking the earliest origin of the Ciba-Geigy half of the Novartis merger.
Edouard Naville founded Sandoz in Basel to manufacture tartaric acid, establishing the second half of the corporate lineage that would eventually merge to form Novartis.
The $30 billion merger of Ciba-Geigy and Sandoz was completed, creating Novartis AG as one of the world's largest pharmaceutical and chemical conglomerates.
Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.
Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.
Novartis agreed to pay $390 million to settle US Department of Justice allegations regarding off-label marketing and kickbacks, a significant legal and financial milestone.
Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.
Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.
On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.
Novartis acquired the German biotechnology company MorphoSys for $2.9 billion ($2.9 billion), strengthening its oncology pipeline with the anti-myelofibrosis drug pelabresib.
Novartis reported $54.5 billion in net sales for FY2025, with operating income reaching $17.644 billion and free cash flow at $17.596 billion, demonstrating strong performance post-Sandoz spin-off.
Entresto faced US generic entry in Q3 2025, resulting in a 43% quarterly sales decline in Q4 and marking the beginning of the end for the company's largest cardiovascular franchise.
Novartis acquired MorphoSys for $2.9 billion to strengthen its oncology pipeline, specifically acquiring the anti-myelofibrosis drug pelabresib and the CD38 antibody MOR202.
Novartis acquired Chinook for $3.5 billion ($3.2B upfront + $300M milestones) to secure late-stage assets for rare kidney diseases, including atrasentan for IgA nephropathy.
Novartis acquired The Medicines Company for $9.7 billion primarily to gain control of the cholesterol-lowering drug inclisiran, a small interfering RNA (siRNA) therapy.
Novartis acquired Advanced Accelerator Applications for $3.9 billion to establish a foothold in the emerging field of radioligand therapy for cancer.
Novartis acquired the remaining stake in Chiron Corporation for $5.1 billion to gain full control of its vaccine and oncology businesses.
Novartis was created on December 20, 1996 through the merger of Ciba-Geigy and Sandoz Laboratories, two Basel-based Swiss companies with combined revenue of approximately CHF 36 billion ($26 billion at then-prevailing rates) — the largest corporate merger in history at the time of announcement in March 1996. The transaction was structured as a merger of equals valued at approximately $63 billion in combined market capitalization. Both predecessors traced their origins to 19th-century Basel chemical-dyestuffs companies that had subsequently expanded into pharmaceuticals: Ciba was founded in 1859 as Bindschedler & Busch, Geigy in 1758 as a chemical-trading house (the oldest of the constituent lineages), and Sandoz in 1886 by Alfred Kern and Edouard Sandoz. Ciba and Geigy had themselves merged in 1970 to form Ciba-Geigy. The strategic rationale combined three threads. First, R&D scale: pharmaceutical research costs were rising into the billions per drug, and combined scale spread that burden across more revenue. Second, portfolio breadth: the merger created a top-three global pharmaceutical company with diversification across prescription drugs, generics (Sandoz), agribusiness, and consumer health. Third, geographic complementarity: Sandoz was stronger in Europe, Ciba-Geigy in the US. The name "Novartis" derives from the Latin novae artes, meaning "new arts" or "new skills."
Novartis spun off its agribusiness division in November 2000 by merging it with AstraZeneca's agribusiness to create Syngenta, a Basel-based crop-protection and seeds company. The spin-off recognized that pharmaceuticals and agribusiness had diverged in capital intensity, R&D timelines, and customer dynamics during the 1990s and that pure-play companies in each industry typically commanded higher valuation multiples than diversified conglomerates. Syngenta listed on the SIX Swiss Exchange and NYSE at the spin-off with annual revenue near $7 billion. The strategic logic was confirmed over the subsequent decade: Syngenta grew its revenue to over $13 billion by 2010, and the agribusiness sector consolidated significantly (Monsanto, DuPont, Bayer-Monsanto, ChemChina-Syngenta), with Syngenta eventually being acquired by China National Chemical Corporation (ChemChina) in 2017 for $43 billion. For Novartis the spin-off was the first of three major portfolio simplifications that ultimately produced the pure-play innovative-medicines company structure of the 2020s, the others being the 2019 Alcon spin-off and the 2023 Sandoz spin-off. Each represented the same strategic philosophy: focus capital on businesses where Novartis could lead globally rather than diversify across unrelated industries.
Novartis built its position in eye care through a multi-stage acquisition of Alcon, the Swiss eye-care specialist founded in 1945. In April 2008 Novartis acquired a 25% stake in Alcon from Nestlé for $11 billion, with an option to acquire majority control. In January 2010 Novartis exercised its option to acquire an additional 52% stake from Nestlé for $28.1 billion, taking control. In 2011 Novartis completed the acquisition of the remaining minority interest, bringing total consideration paid for Alcon to approximately $52 billion. Alcon was integrated into Novartis as the eye-care division and built to revenue near $10 billion by the mid-2010s. By 2017-2018, however, Alcon's growth had stalled, surgical and vision-care competitive dynamics had compressed margins, and the division was no longer earning its cost of capital. On April 9, 2019 Novartis spun off Alcon as an independent SIX Swiss Exchange and NYSE-listed company through a distribution to existing shareholders. Alcon's market capitalization at separation was approximately $30 billion and grew to roughly $40-45 billion by 2024 with revenue near $9.6 billion. The Alcon transaction sequence is generally cited as the costliest portfolio mistake in Novartis history — total capital deployed materially exceeded the spin-off value — but it removed a structural drag on group margins and growth.
On October 4, 2023 Novartis completed the spin-off of Sandoz, its generics and biosimilars division, distributing Sandoz shares to existing Novartis shareholders. Sandoz began trading on the SIX Swiss Exchange and OTC in the United States as an independent company with annual revenue near $9.6 billion. The spin-off completed the multi-decade portfolio simplification of Novartis from a diversified pharmaceutical-and-chemicals conglomerate into a pure-play innovative-medicines company. Sandoz had been a co-anchor of Novartis since the 1996 merger and had built a leading position in biosimilars — generic versions of biologic drugs such as Hyrimoz (adalimumab biosimilar) and Ziextenzo (pegfilgrastim biosimilar) — alongside its traditional small-molecule generics business. The strategic rationale was that generics and innovative medicines had diverged in capital allocation, R&D priorities, and competitive dynamics: generics required scale and operational efficiency to compete with Teva, Viatris, Sun Pharma, and Indian generics specialists, while innovative medicines required differentiated R&D investment and premium pricing. Combined the businesses produced a blended financial profile that neither pure-play structure investors would have preferred. Post spin-off, Novartis's revenue dropped from approximately $50 billion to roughly $45 billion on a continuing-operations basis, but operating margin and R&D intensity both improved materially. The 2023 spin-off completed the transformation of Novartis into one of the most focused large-cap pharma businesses in the industry.
Following the 2019 Alcon spin-off and the 2023 Sandoz spin-off, Novartis operates as a pure-play innovative medicines company with 2024 revenue of approximately $50.3 billion and operating margin near 34%. The portfolio is concentrated in five therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; oncology; and hematology. Five flagship growth medicines account for the majority of growth: Entresto (heart failure, $7.8 billion 2024), Cosentyx (psoriasis/PsA/AS, $6.3 billion 2024), Kisqali (breast cancer, $2.6 billion 2024), Kesimpta (multiple sclerosis, $3.2 billion 2024), and Pluvicto (prostate cancer radioligand, $1.4 billion 2024). The pipeline emphasizes four technology platforms — gene therapy (Zolgensma for SMA), radioligand therapy (Pluvicto and the Endocyte heritage), siRNA (Leqvio via The Medicines Company acquisition), and traditional small molecules and biologics. The strategy is explicitly to defend Entresto from US patent expiry in 2025-2026 through pipeline assets like Pelacarsen (cardiovascular Lp(a)), Iptacopan (hematology/renal), Atrasentan (kidney disease), and continued expansion of Pluvicto into earlier prostate-cancer settings. Geographic mix is approximately 36% US, 27% Europe, and 37% Rest of World. Manufacturing remains anchored in Basel, with major US sites in New Jersey, North Carolina, and Indianapolis.